EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Rheumatoid Factor: Diagnostic and Prognostic Performance and Therapeutic Implications in Rheumatoid Arthritis

Tasuku Togashi, Ryuhei Ishihara, Ryu Watanabe iD, Mayu Shiomi iD, Yuya Yano, Yuhei Fujisawa iD, Masao Katsushima iD, Kazuo Fukumoto iD, Shinsuke Yamada, Motomu Hashimoto

Journal of Clinical Medicine · 25.02.2025 · 14 (5) · 1529

DOI: 10.3390/jcm14051529 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 25.02.2025. Verfasst von Tasuku Togashi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 188 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rheumatoid factor (RF) is the first autoantibody identified in rheumatoid arthritis (RA) which targets the fragment crystallizable (Fc) region of immunoglobulin (Ig) G. Although IgM isotype is predominant, other Ig isotypes, including IgG and IgA, also exist. While RF is not specific to RA, it remains a valuable serological test for diagnosing the disease, as evidenced by its inclusion in the 2010 classification criteria for RA based on elevated serum RF levels. RF is also associated with RA severity, including joint damage and extra-articular manifestations, serving as a poor prognostic factor and aiding in the identification of difficult-to-treat RA. Recent studies have demonstrated that high serum RF levels are associated with a reduced response to tumor necrosis factor (TNF) inhibitors. In contrast, anti-TNF antibodies lacking the Fc portion have shown stable efficacy in RA patients regardless of baseline RF levels. These findings reaffirm the clinical significance of RF measurement, 80 years after its initial discovery. This review explores the diagnostic and prognostic significance of RF and its impact on treatment selection in RA management.

Schlagwörter

Stichwörter der Autor:innen

anti-citrullinated protein antibodiesrheumatoid arthritisrheumatoid factortumor necrosis factor

Autor:innen und Institutionen

  • Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.

ORCID-Profile: Ryu Watanabe, Mayu Shiomi, Yuhei Fujisawa, Masao Katsushima, Kazuo Fukumoto

Zitieren

APA

Togashi, T., Ishihara, R., Watanabe, R., Shiomi, M., Yano, Y., Fujisawa, Y., Katsushima, M., Fukumoto, K., Yamada, S., & Hashimoto, M. (2025). Rheumatoid Factor: Diagnostic and Prognostic Performance and Therapeutic Implications in Rheumatoid Arthritis. Journal of Clinical Medicine, 14(5), 1529. https://doi.org/10.3390/jcm14051529

Vancouver

Togashi T, Ishihara R, Watanabe R, Shiomi M, Yano Y, Fujisawa Y, et al. Rheumatoid Factor: Diagnostic and Prognostic Performance and Therapeutic Implications in Rheumatoid Arthritis. Journal of Clinical Medicine. 2025;14(5):1529. doi:10.3390/jcm14051529

BibTeX
@article{Togashi2025,
  author = {Togashi, Tasuku and Ishihara, Ryuhei and Watanabe, Ryu and Shiomi, Mayu and Yano, Yuya and Fujisawa, Yuhei and Katsushima, Masao and Fukumoto, Kazuo and Yamada, Shinsuke and Hashimoto, Motomu},
  title = {Rheumatoid Factor: Diagnostic and Prognostic Performance and Therapeutic Implications in Rheumatoid Arthritis},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {5},
  pages = {1529},
  doi = {10.3390/jcm14051529}
}
Kostenlos starten →